Ever exposed to | ||||
---|---|---|---|---|
Total | Anti-TNFα | Anakinra | Conventional DMARD only | |
N with prior malignancy | 122 | 72 | 11 | 43 |
Patient-years of follow-up | 379 | 198 | 31 | 159 |
Recurrent malignancies | 15 | 9 (5 f, 4 m) | 1 (m) | 5 (4 f, 1 m) |
Breast cancer | 5 | 4 (f) | - | 1(f) |
Lung cancer | 3 | 1 (m) | 1 (m) | 1 (f) |
Bladder cancer | 2 | 1 (m)# | - | 1 (f) |
Liposarcoma | 1 | 1 (m) | - | - |
Melanoma | 1 | 1 (f) | ||
Signet-ring cell carcinoma | 1 | - | - | 1 (f) |
Testicular cancer | 1 | 1 (m)# | - | - |
Metastasis of unknown origin | 1 | 1 (m) |